Skip to main content
EJNMMI Research

Table 3 Univariate analysis for recurrence-free survival and distant recurrence-free survival

From: [18F]FDG uptake of bone marrow on PET/CT for predicting distant recurrence in breast cancer patients after surgical resection

Variables

Recurrence-free survival

Distant recurrence-free survival

p value*

HR (95% CI)

p value*

HR (95% CI)

Age (1-year increase)

0.517

1.01 (0.98–1.04)

0.836

0.98 (0.94–1.02)

Menopausal status (pre vs. post)

0.998

1.01 (0.52–1.94)

0.224

0.58 (0.24–1.40)

T stage

    

 T1 stage vs. T2 stage

< 0.001

8.43 (2.51–28.31)

0.034

5.24 (1.13–24.30)

 T1 stage vs. T3–4 stage

< 0.001

25.08 (7.06–89.10)

< 0.001

26.04 (5.62–120.78)

N stage (N0 vs. N1–3)

0.001

2.97 (1.53–5.77)

0.044

2.48 (1.03–5.99)

Histologic grade

    

 Grade 1 vs. grade 2

0.419

1.59 (0.52–4.87)

0.403

1.94 (0.41–9.12)

 Grade 1 vs. grade 3

0.003

5.03 (1.71–14.81)

0.036

5.07 (1.11–23.20)

ER status (positive vs. negative)

< 0.001

3.93 (2.04–7.57)

< 0.001

5.07 (2.07–12.43)

PR status (positive vs. negative)

< 0.001

4.82 (2.32–10.01)

0.031

2.68 (1.09–6.57)

HER2 status (positive vs. negative)

0.612

1.19 (0.61–2.29)

0.872

0.93 (0.39–2.24)

Ki67 index (negative vs. positive)

0.057

5.77 (0.98–18.82)

0.090

2.89 (0.85–9.88)

Triple negative tumor (no vs. yes)

< 0.001

3.70 (1.77–7.73)

< 0.001

5.07 (2.00–12.84)

NLR (1.00 increase)

0.221

1.11 (0.94–1.33)

0.052

1.21 (0.99–1.46)

PLR (1.0 increase)

0.007

1.01 (1.00–1.01)

0.001

1.01 (1.00–1.01)

Maximum SUV (1.00 increase)

< 0.001

1.07 (1.03–1.11)

0.032

1.06 (1.01–1.12)

MTV (1.00 cm3 increase)

< 0.001

1.01 (1.01–1.01)

< 0.001

1.01 (1.01–1.02)

TLG (1.00 g increase)

< 0.001

1.00 (1.00–1.01)

< 0.001

1.01 (1.00–1.01)

BM SUV (1.00 increase)

0.041

1.86 (1.03–4.72)

0.048

2.32 (1.02–5.99)

BLR (1.00 increase)

< 0.001

22.34 (4.70–46.23)

< 0.001

29.76 (11.05–69.34)

  1. ER estrogen receptor, PR progesterone receptor, HER2 human epidermal growth factor receptor 2, NLR neutrophil-to-lymphocyte ratio, PLR platelet-to-lymphocyte ratio, SUV standardized uptake value, MTV metabolic tumor volume, TLG total lesion glycolysis, BM bone marrow, BLR bone marrow-to-liver uptake ratio, HR hazard ratio, CI confidence interval
  2. *Statistically significant for p value < 0.003
Back to article page